Moreover, in the metastatic setting, no differences in progression-free survival (PFS) or overall survival (OS) have been identified between patients with HER2-positive breast cancer who received weight-based trastuzumab Q3W or fixed doses every 4 weeks (Q4W)12. The gene discussed is ERBB2; the disease is breast cancer.